

References

Charles G. Mullighan. How advanced are we in targeting novel subtypes of ALL? Best Pract Res Clin Haematol. 2019 Dec;32(4):101095

Roex G et al CAR T in B ALL Review of clinical trials Pharmaceutics 2020

ALL EBMT recommendations for alloSCT 2020

Inbar T, Rowe JM, Horowitz NA. Which patients should I **transplant** with acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017 Sep;30(3):249-260

Fatiyizzo et al Physiopathology of T ALL Frontiers in Oncology 2020

Apel A et al Safety and efficacy of blinatumomab a real world data Annals of hematology 2020

Gökbuget N. How should we treat a patient with **relapsed Ph-negative B-ALL** and what novel approaches are being investigated? Best Pract Res Clin Haematol. 2017 Sep;30(3):261-274

Frey NV, Luger SM. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood 2015;126:589–96.

Wolach O, Amitai I, DeAngelo DJ. Current challenges and opportunities in treating **adult patients with Philadelphia-negative acute lymphoblastic leukaemia**. Br J Haematol. 2017 Dec;179(5):705-723

Lee SHR, Yang JJ. **Pharmacogenomics** in acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2017 Sep;30(3):229-236

References

Roberts KG. The biology of **Philadelphia chromosome-like ALL**. Best Pract Res Clin Haematol. 2017 Sep;30(3):212-221

Maese L, Tasian SK, Raetz EA. How is the **Ph-like** signature being incorporated into **ALL therapy**? Best Pract Res Clin Haematol. 2017 Sep;30(3):222-228

Wieduwilt MJ. How should we treat **older adults with Ph+ adult ALL** and what novel approaches are being investigated? Best Pract Res Clin Haematol. 2017 Sep;30(3):201-211

Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to **treat Philadelphia chromosome-positive acute lymphoblastic leukemia**? Best Pract Res Clin Haematol. 2017 Sep;30(3):193-200

O'Dwyer KM, Liesveld JL. **Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults**: Current treatment and novel therapies. Best Pract Res Clin Haematol. 2017 Sep;30(3):184-192

Boissel N. How should we treat the **AYA patient** with newly diagnosed ALL? Best Pract Res Clin Haematol. 2017 Sep;30(3):175-183

Graux C. **Biology** of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance. Transfus Apher Sci. 2011 Apr;44(2):183-9. Review

Giebel S. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation 2019 ; 54:798–809